BioRad Laboratories (BIO)
(Delayed Data from NYSE)
$284.60 USD
+42.65 (17.63%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $285.16 +0.56 (0.20%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BIO 284.60 +42.65(17.63%)
Will BIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIO
Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 10th
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Other News for BIO
Bio-Rad (BIO) Stock Surges Over 15%
UBS Increases Price Target for Bio-Rad (BIO) to $325
RBC Capital Raises Price Target for Bio-Rad Laboratories (BIO) to $409 | BIO Stock News
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
BIO Crosses Above Key Moving Average Level